Modra

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC

11 february 2021

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC, Convenient Approach Amid COVID-19 Pandemic

Article published in ASCO Daily News, February 10 2021

 




News

Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
Read more

Modra's Novel Approach

Boosted Oral Taxanes    
Learn more

Events

     
Read more